[go: up one dir, main page]

MX2010009244A - Derivado de amida, y composicion farmaceutica que contiene el mismo. - Google Patents

Derivado de amida, y composicion farmaceutica que contiene el mismo.

Info

Publication number
MX2010009244A
MX2010009244A MX2010009244A MX2010009244A MX2010009244A MX 2010009244 A MX2010009244 A MX 2010009244A MX 2010009244 A MX2010009244 A MX 2010009244A MX 2010009244 A MX2010009244 A MX 2010009244A MX 2010009244 A MX2010009244 A MX 2010009244A
Authority
MX
Mexico
Prior art keywords
formula
pharmaceutical composition
composition containing
same
amide derivative
Prior art date
Application number
MX2010009244A
Other languages
English (en)
Inventor
Shiro Kato
Hiroshi Harada
Hiroshi Yamazaki
Takanori Nakamura
Yoko Kan
Yoshimi Hirokawa
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Publication of MX2010009244A publication Critical patent/MX2010009244A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un compuesto que tiene una fuerte afinidad por los receptores 4 de serotonina, el cual es útil como un agente que promueve la enterocinesis o un agente que mejora la función del tracto digestivo; específicamente, se describe un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo; también descrita específicamente, es una composición farmacéutica que contiene un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable del mismo; [en la fórmula (1), Ar representa un grupo representado por la fórmula (Ar-1) o la fórmula (Ar-2)]. (ver fórmulas).
MX2010009244A 2008-02-21 2009-02-20 Derivado de amida, y composicion farmaceutica que contiene el mismo. MX2010009244A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008040029 2008-02-21
PCT/JP2009/053011 WO2009104729A1 (ja) 2008-02-21 2009-02-20 アミド誘導体及びそれを含有する医薬組成物

Publications (1)

Publication Number Publication Date
MX2010009244A true MX2010009244A (es) 2010-09-24

Family

ID=40985606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009244A MX2010009244A (es) 2008-02-21 2009-02-20 Derivado de amida, y composicion farmaceutica que contiene el mismo.

Country Status (14)

Country Link
US (1) US7906510B2 (es)
EP (1) EP2256114B1 (es)
JP (1) JP5101639B2 (es)
KR (1) KR101586507B1 (es)
CN (1) CN102015697B (es)
AU (1) AU2009216149B2 (es)
BR (1) BRPI0907833A2 (es)
CA (1) CA2713412C (es)
ES (1) ES2478042T3 (es)
IL (1) IL207423A (es)
MX (1) MX2010009244A (es)
RU (1) RU2481343C2 (es)
TW (1) TWI423967B (es)
WO (1) WO2009104729A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513044A (zh) * 2017-09-20 2017-12-26 安徽修制药有限公司 一种枸橼酸莫沙必利的绿色环保合成方法
WO2019131891A1 (ja) * 2017-12-28 2019-07-04 大日本住友製薬株式会社 苦味がマスキングされた薬物含有粒子及び該薬物含有粒子を含む製剤
US20210369624A1 (en) * 2018-06-01 2021-12-02 Sumitomo Dainippon Pharma Co., Ltd. Solid oral dosage form having excellent dissolution properties
CN110938068B (zh) * 2019-11-06 2022-12-23 广东东阳光药业有限公司 N-(吗啉-2-基甲基)酰胺衍生物及其用途
CN115975210B (zh) * 2023-01-14 2023-07-14 厦门立方幻境科技有限公司 一种医用硅胶及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
TW243449B (es) 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
US5395832A (en) 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
AU710037B2 (en) * 1995-05-23 1999-09-09 Janssen Pharmaceutica N.V. (2-morpholinylmethyl)benzamide derivatives
JPH111472A (ja) * 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
CA2330475A1 (en) * 1998-04-28 1999-11-04 Dainippon Pharmaceutical Co., Ltd. 1-¬(1-substituted-4-piperidinyl)methyl|-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
JP2000080081A (ja) 1998-06-24 2000-03-21 Dainippon Pharmaceut Co Ltd １―〔（１―置換―４―ピペリジニル）メチル〕―４―ピペリジン誘導体及びそれを含有する医薬組成物
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
EP1289965B1 (en) * 2000-05-25 2005-10-26 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2005170933A (ja) 2003-11-14 2005-06-30 Dainippon Pharmaceut Co Ltd （ｓ）−４−アミノ−５−クロロ−２−メトキシ−ｎ−［１−［１−（２−テトラヒドロフリルカルボニル）−４−ピペリジニルメチル］−４−ピペリジニル］ベンズアミドからなる医薬

Also Published As

Publication number Publication date
TWI423967B (zh) 2014-01-21
CN102015697A (zh) 2011-04-13
EP2256114B1 (en) 2014-06-25
IL207423A (en) 2016-06-30
BRPI0907833A2 (pt) 2016-08-02
HK1145837A1 (en) 2011-05-06
KR101586507B1 (ko) 2016-01-19
EP2256114A4 (en) 2012-05-09
AU2009216149A1 (en) 2009-08-27
TW200951129A (en) 2009-12-16
JPWO2009104729A1 (ja) 2011-06-23
US20100249399A1 (en) 2010-09-30
IL207423A0 (en) 2010-12-30
ES2478042T3 (es) 2014-07-18
EP2256114A1 (en) 2010-12-01
KR20100126684A (ko) 2010-12-02
CA2713412A1 (en) 2009-08-27
RU2481343C2 (ru) 2013-05-10
CN102015697B (zh) 2015-06-17
RU2010138788A (ru) 2012-03-27
US7906510B2 (en) 2011-03-15
WO2009104729A1 (ja) 2009-08-27
CA2713412C (en) 2016-03-22
AU2009216149B2 (en) 2013-05-23
JP5101639B2 (ja) 2012-12-19

Similar Documents

Publication Publication Date Title
TW200728307A (en) Novel spirochromanone derivatives
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
UA105229C2 (uk) Фармацевтичний склад
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
TW200612958A (en) Substituted imidazole derivatives
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
WO2006049835A3 (en) Indole and benzimidazole derivatives
MY151986A (en) Adamantyl diamide derivatives and uses of same
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
MY151295A (en) Pyrimidyl indoline compound
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status